Transfusion medicine encompasses various care and research lines around immunohematology, cellular immunotherapy, congenital coagulopathies and regenerative medicine. A. Obtaining red blood cells generated in vitro to enhance the panel of blood donors with minority blood groups. N. Nogues group has established a technology for immortalization of red blood cell lines to improve panels. B. Technological improvements for diagnosis of hereditary haemorrhagic diseases. F. Vidal group has developed and validated new NGS technologies in the study of these disorders. C. Creation of a bank of T cells. S. Querol group is developing strategies for generation and ex vivo production of T lymphocytes to treat infectious and oncohematological diseases. D. Blood safety. S. Sauleda group is conducting epidemiological surveillance on emerging and re-emerging transfusion-transmitted infectious diseases and is developing immunological and molecular tools to better understand their physiopathology.
Group Leader
Rafael Parra López
Principal Investigator (PI)
Alejandro Madrigal Fernandez, Francisco Vidal Perez, Nuria Nogues Galvez, Sergi Querol Giner
Researchers
Carme Canals Suris, Cecilia Gonzalez Santesteban, Cristina Prat Vidal, Dinara Samarkanova, Elena Gomez Massa, Emma Enrich Rande, Francesc Rudilla Salvador, Gemma Aran Canals, Irene Corrales Insa, Iris Garcia Martinez, Joaquim Delgadillo Duarte, Julio Castaño Cardoso, Laia Closa Gil, Laia Miquel Serra, Laura Martin Fernandez, Lluis Martorell Cedres, Luciano Rodriguez Gomez, Margarita Codinach Creus, Maria Jose Herrero Mata, Maria Piron, Marta Bes Maijo, Marta Rodriguez Aliberas, Nina Borras Agusti, Rut Mora Buch, Silvia Sauleda Oliveras, Rubén Escribà Piera, Sara Morini, Gloria Soria Guerrero
PhD Students
Carlos Hobeich Naya, Carme Azqueta Molluna, Elena Valdivia Garcia, Helena Pasamar Garijo, Jesus Fernandez Sojo, Miriam Aylagas Garcia, Monica Linares Alberich, Raquel Gil Muro, Silvia Torrents Zapata, Sofia Alonso Mateos, Veronica Pons Escoll
Lab Technicians
Angie Rico Blazquez, Carina Lera Asensio, Lorena Ramirez Orihuela, Maria Tomas Marin, Mercedes Martinez Fernandez, Natalia Comes Fernandez, Sergio Huertas Torres
Nursing and Technical Staff
Elisenda Farssac Busquets
16
PUBLICATIONS
50.0%
%Q1
97
IMPACT FACTOR
6.07
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Bes M, Costafreda MI, Riveiro-Barciela M, Piron M, Rico A, Quer J, Puig L, Sauleda S
Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017‒2020
EMERG INFECT DIS 2022 Jan;28(1):157-165
DOI: doi: 10.3201/eid2801.211466
IF: 16.126
Piron M, Salvador F, Caballero E, Sánchez-Montalvá A, Bes M, Casamitjana N, Puig L, Molina I, Sauleda S
HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience
VIRUSES 2022, 14, 1975
DOI: doi: 10.3390/v14091975
IF: 5.818
Álvarez-Palomo B, Veiga A, Raya A, Codinach M, Torrents S, Ponce Verdugo L, Rodriguez-Aierbe C, Cuellar L, Alenda R, Arbona C, Hernández-Maraver D, Fusté C, Querol S
Public Cord Blood Banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells
STEM CELL RES THER 2022 Aug 12;13(1):408
DOI: doi: 10.1186/s13287-022-02961-6
IF: 8.098
Vives J, Hernández J, Mirabel C, Puigdomenech-Poch M, Romeo-Guitart D, Marmolejo-Martínez-Artesero S, Cabrera-Pérez R, Jaramillo J, Kumru H, García-López J, Vidal-Samsó J, Navarro X, Coll-Bonet R
Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton’s Jelly Mesenchymal Stromal Cells: Proof of Concept and Regulatory Compliance
CELLS 2022 Jul 8;11(14):2153
DOI: doi: 10.3390/cells11142153
IF: 7.666
Fernandez-Sojo J, Delgadillo J, Vives J, Rodriguez L, Mendoza A, Azqueta C, Garcia-Buendia A, Valdivia E, Martorell L, Rubio-Lopez N, Linares M, Alonso S, Ancochea A, García-Rey E, García-Muñoz N, Medina L, Querol S
A hub-and-spoke model to deliver effective access to chimeric antigen receptor T-cell therapy in a public health network: the Catalan Blood and Tissue Bank experience
CYTOTHERAPY 2022 Aug 27:S1465-3249(22)00741-1
DOI: doi: 10.1016/j.jcyt.2022.07.011
IF: 6.196
OSCAR-iNK: Off-the-Shelf iPSC-derived next generation CAR-NK cells for solid tumor allogenic immunotherapy
Principal Investigator: Sergi Querol Giner
Agency: Agencia Estatal de Investigación
Funding: 97,632 €
Period: 2022 – 2025
HEMO-GAS: Recreating the embryonic niche for hematopoietic stem cell production and derivatives in human gastruloids
Principal Investigator: Núria Nogués Gálvez
Agency: Agencia Estatal de Investigación
Funding: 120,374 €
Period: 2021 - 2024
Addressing inherited haemorrhagic disorders of complex aetiology through the application of a common exome sequencing strategy
Principal Investigator: Francisco Vidal Perez
Agency: Instituto de Salud Carlos III
Funding: 99,220 €
Period: 2019 – 2022
iPS-PANIA: Allogeneic IPSCs from homozygous umbilical cord blood units for high-prevalence haplotypes
Principal Investigator: Sergi Querol Giner
Agency: Agencia Estatal de Investigación
Funding: 197,804 €
Period: 2018 – 2022
ID-VITRORED: Obtaining in vitro red blood cells from IPSCs of donors with erythrocyte phenotypes selected and optimised by genomic editing, as an alternative to current red cell panels
Principal Investigator: Núria Nogués Gálvez
Agency: Agencia Estatal de Investigación
Funding: 249,614 €
Period: 2018 – 2022
eCOREs
